BRAF and melanoma: Sorafenib has shown little activity as a single agent in the treatment of malignant melanoma, irrespective of B-Raf status [4], however in combination with carboplatin it has shown promising clinical activity [5] and is presently being tested in several clinical trials in melanoma either alone or in combination with other agents .